Clinical Trials Logo

Vaccines clinical trials

View clinical trials related to Vaccines.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06259487 Recruiting - Heart Failure Clinical Trials

Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.

VACCINE-CHF
Start date: September 15, 2023
Phase: N/A
Study type: Interventional

This prospective, single-centre, open-label, randomized study aims to determine whether coordinated care in administering protective vaccinations (against Respiratory Syncytial Virus (RSV) and influenza) impacts the prognosis of patients with chronic heart failure. The main question it aims to answer is: • Does coordinated care through vaccinations improve the prognosis of patients with chronic heart failure?

NCT ID: NCT06179446 Recruiting - Influenza Clinical Trials

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Start date: December 13, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine. This study is seeking for participants who are: - between the age of 18 to 49 years old. - willing and able to follow with all scheduled visits, treatment plan, laboratory tests, lifestyle changes, and other study procedures. - healthy as confirmed by medical history, physical examinations, and the study doctor. - capable of signing informed consent. Participants will receive either: - the pdmFlu Vaccine, - a licensed Influenza Vaccine (QIV) - a placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will not know which vaccine they receive. Participants will receive the study vaccines as a single shot in the arm at day 1 and at day 21. The study will compare participant experiences to help understand if the pdmFlu Vaccine is safe and effective. Participants will take part in this study for up to 8 months. During this time, the participants will receive the study vaccine and take part in follow-up visits.

NCT ID: NCT05586204 Recruiting - COVID-19 Clinical Trials

Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up

Start date: October 18, 2022
Phase: N/A
Study type: Interventional

This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text messages affect the take-up of bivalent COVID-19 booster. The investigators will test the impact of sending text reminders as well as the importance of elevating vaccination intentions, facilitating action, and their combination.

NCT ID: NCT05586178 Recruiting - COVID-19 Clinical Trials

Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake

Start date: October 18, 2022
Phase: N/A
Study type: Interventional

This study investigates different ways to elevate intentions to get the COVID-19 booster via text-based reminders, including providing information about the booster and leveraging the consistency principle. The proposed randomized controlled trial will examine the impact of these reminders on booster uptake.

NCT ID: NCT05586165 Recruiting - COVID-19 Clinical Trials

Effects of Prompt to Bundle COVID-19 Booster and Flu Shot

Start date: October 18, 2022
Phase: N/A
Study type: Interventional

This randomized controlled trial investigates whether text-based reminders can increase the bivalent COVID-19 booster uptake and whether text-based reminders that mention the opportunity to bundle the COVID-19 booster with the flu shot within the same appointment can increase take-up of both the COVID-19 booster and the flu vaccine.

NCT ID: NCT05494047 Recruiting - Influenza Clinical Trials

Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile

TetraFluVac
Start date: July 14, 2022
Phase: Phase 3
Study type: Interventional

This study compares the immunogenity and safety of quadrivalent inactivated influenza vaccines. The experimental group receives the quadrivalent influenza vaccine developed by Sinovac Biotech Co., Ltd and the control group immunized with Vaxigrip Tetra™. The group has 1600 persons from general population 3 years and older. The design is double-blind and randomized. The primary outcome is the immunogenicity against the 4 strains of influenza included in both vaccines.

NCT ID: NCT05084950 Recruiting - COVID-19 Clinical Trials

Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)

MonaVacc
Start date: July 1, 2021
Phase:
Study type: Observational

Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.

NCT ID: NCT04388033 Recruiting - Neoplasms Clinical Trials

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

Start date: December 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-naïve patients after resection of glioblastoma.

NCT ID: NCT02242968 Recruiting - Clinical trials for Physiological Effects of Drugs

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

Start date: April 24, 2023
Phase:
Study type: Observational

Background: - Vaccines and antiviral therapies help prevent and treat diseases. Researchers need a group of healthy volunteers for clinical trials. Clinical trials are studies that test these vaccines and therapies in people. Objective: - To screen volunteers for clinical trials for investigational or licensed vaccines or drugs to treat or prevent virus infections. Eligibility: - Healthy adults age 18 or older. Design: - Participants will be asked questions about their health history, including sexual activity and drug use. They will give blood samples. They may have a physical exam. They may give a urine sample. - Participants may have the inside of their nose either swabbed or washed with some fluid. The fluid will be collected. They may give a stool sample. - Participants may have an electrocardiogram. Soft, sticky patches will be attached to participants chest, arms, and legs. They will lie still on a table while the patches detect the heart s electrical signals. A machine will record these signals. - Participants may have lung function tests. These tests measure the volume of air moving in and out of the lungs. Participants will forcibly blow air into a machine. - Participants will be told if any tests show a medical problem. - If a participant is eligible and decides to join an investigational clinical trial, researchers will explain the study and the risks involved. Participants will sign a separate consent for that clinical trial.